AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
papaverine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| spasmolytics with a papaverine-like action | 2056 | 58-74-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
| 0.10 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 25.26 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 57.20 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 11 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.07 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.80 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.696 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.521 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 54.954 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 48.753 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 11.050 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 28.010 | % | High | 1 |
| herg | hERG pIC50 | 4.726 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 32.810 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 151.705 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 4.340 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 50 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,DDR1,EIF2AK3,EPHB4,ERBB2,GRK2,IRAK3,JAK1,MAP2K3,MAP3K21,MAPK12,MAPK7,PDK4,PIK3CB,PIK3CD,PRKDC,SIK2,SIK3,TTK | 23 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.721 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 170.608 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 9.680 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 2.070 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 20.940 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 207.970 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 73.360 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 7.300 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 311.172 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Creatinine renal clearance decreased | 159.05 | 64.91 | 39 | 1153 | 18860 | 90608395 |
| Sedation complication | 158.10 | 64.91 | 38 | 1154 | 16906 | 90610349 |
| Blood calcium decreased | 136.33 | 64.91 | 38 | 1154 | 30144 | 90597111 |
| Renal function test abnormal | 131.76 | 64.91 | 28 | 1164 | 7163 | 90620092 |
| Orthostatic hypotension | 124.08 | 64.91 | 38 | 1154 | 41789 | 90585466 |
| Creatinine renal clearance increased | 121.67 | 64.91 | 23 | 1169 | 3258 | 90623997 |
| Drug abuse | 120.86 | 64.91 | 44 | 1148 | 82303 | 90544952 |
| Sedation | 114.68 | 64.91 | 37 | 1155 | 48134 | 90579121 |
| Cognitive disorder | 105.19 | 64.91 | 38 | 1154 | 69369 | 90557886 |
| Depressed level of consciousness | 99.73 | 64.91 | 37 | 1155 | 72747 | 90554508 |
| Hypotension | 90.82 | 64.91 | 55 | 1137 | 325342 | 90301913 |
| Balance disorder | 89.38 | 64.91 | 37 | 1155 | 97043 | 90530212 |
| Multiple drug therapy | 87.85 | 64.91 | 20 | 1172 | 6989 | 90620266 |
| Toxicity to various agents | 75.97 | 64.91 | 47 | 1145 | 287799 | 90339456 |
| Constipation | 74.54 | 64.91 | 46 | 1146 | 280349 | 90346906 |
| Drug interaction | 65.03 | 64.91 | 42 | 1150 | 276411 | 90350844 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 350.71 | 73.78 | 129 | 532 | 229007 | 42391667 |
| Drug abuse | 183.35 | 73.78 | 66 | 595 | 104705 | 42515969 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 312.56 | 53.98 | 154 | 1722 | 480401 | 110107022 |
| Drug abuse | 277.43 | 53.98 | 106 | 1770 | 177305 | 110410118 |
| Creatinine renal clearance decreased | 143.42 | 53.98 | 39 | 1837 | 21776 | 110565647 |
| Sedation complication | 142.30 | 53.98 | 38 | 1838 | 19817 | 110567606 |
| Blood calcium decreased | 120.12 | 53.98 | 38 | 1838 | 35807 | 110551616 |
| Renal function test abnormal | 118.46 | 53.98 | 28 | 1848 | 8918 | 110578505 |
| Creatinine renal clearance increased | 113.46 | 53.98 | 23 | 1853 | 3602 | 110583821 |
| Depressed level of consciousness | 112.63 | 53.98 | 49 | 1827 | 112229 | 110475194 |
| Overdose | 99.65 | 53.98 | 57 | 1819 | 233737 | 110353686 |
| Orthostatic hypotension | 97.28 | 53.98 | 38 | 1838 | 66211 | 110521212 |
| Sedation | 91.94 | 53.98 | 37 | 1839 | 69646 | 110517777 |
| Drug interaction | 89.38 | 53.98 | 71 | 1805 | 500112 | 110087311 |
| Cognitive disorder | 87.06 | 53.98 | 38 | 1838 | 87473 | 110499950 |
| Multiple drug therapy | 80.07 | 53.98 | 20 | 1856 | 7994 | 110579429 |
| Balance disorder | 79.64 | 53.98 | 39 | 1837 | 116521 | 110470902 |
| Hypotension | 66.13 | 53.98 | 61 | 1815 | 523788 | 110063635 |
| Alcohol interaction | 56.46 | 53.98 | 13 | 1863 | 3681 | 110583742 |
| Constipation | 55.73 | 53.98 | 47 | 1829 | 357739 | 110229684 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A03AD01 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS Papaverine and derivatives |
| ATC | G04BE02 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs used in erectile dysfunction |
| ATC | G04BE52 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs used in erectile dysfunction |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D010726 | Phosphodiesterase Inhibitors |
| MeSH PA | D014665 | Vasodilator Agents |
| MeSH PA | D064804 | Urological Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
| CHEBI has role | CHEBI:55323 | antidiarrhoeal drug |
Related Drugs by ATC class:
A03AD Papaverine and derivatives 2 drugs
G04BE Drugs used in erectile dysfunction 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Cerebral ischemia | indication | 287731003 | |
| Peripheral vascular disease | indication | 400047006 | |
| Sinus tachycardia | contraindication | 11092001 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Complete atrioventricular block | contraindication | 27885002 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Angina pectoris | contraindication | 194828000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
| Disorder of coronary artery | contraindication | 414024009 | |
| Cardiac Conduction Delay | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.36 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.14 | CHEMBL | |||||
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Enzyme | Ki | 6.55 | CHEMBL | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Enzyme | WOMBAT-PK | |||||||
| Acetylcholinesterase | Enzyme | IC50 | 4.61 | CHEMBL | |||||
| cGMP-specific 3',5'-cyclic phosphodiesterase | Enzyme | IC50 | 5.06 | CHEMBL | |||||
| cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | Enzyme | IC50 | 7.77 | CHEMBL | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 6.12 | DRUG MATRIX | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | IC50 | 6.09 | DRUG MATRIX | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Enzyme | IC50 | 5.85 | CHEMBL | |||||
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Enzyme | IC50 | 5.64 | CHEMBL | |||||
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Enzyme | Ki | 6.38 | CHEMBL | |||||
| Protein-arginine deiminase type-4 | Enzyme | IC50 | 4.41 | CHEMBL | |||||
| Phosphodiesterase 1 | Enzyme | IC50 | 5.05 | CHEMBL | |||||
| Serine hydroxymethyltransferase, mitochondrial | Enzyme | IC50 | 5.57 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | IC50 | 4.61 | CHEMBL | |||||
| Cyclic nucleotide phosphodiesterase PDE3A | Enzyme | IC50 | 6.21 | CHEMBL | |||||
| Cyclic AMP-specific phosphodiesterase SSPDE4A1A | Enzyme | IC50 | 5.77 | CHEMBL | |||||
| cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | Enzyme | IC50 | 7.44 | CHEMBL | |||||
| Phosphodiesterase 1 | Enzyme | IC50 | 5.06 | CHEMBL | |||||
| Phosphodiesterase 1 | Enzyme | IC50 | 4.92 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019875 | VUID |
| N0000147960 | NUI |
| D02218 | KEGG_DRUG |
| 61-25-6 | SECONDARY_CAS_RN |
| 4017430 | VANDF |
| 4019875 | VANDF |
| C0030350 | UMLSCUI |
| EV1 | PDB_CHEM_ID |
| CHEMBL19224 | ChEMBL_ID |
| DB01113 | DRUGBANK_ID |
| CHEMBL98123 | ChEMBL_ID |
| D010208 | MESH_DESCRIPTOR_UI |
| 4680 | PUBCHEM_CID |
| 13147 | IUPHAR_LIGAND_ID |
| DAA13NKG2Q | UNII |
| 203132 | RXNORM |
| 4553 | MMSL |
| 5230 | MMSL |
| d00695 | MMSL |
| 000694 | NDDF |
| 004522 | NDDF |
| 372784001 | SNOMEDCT_US |
| 40404004 | SNOMEDCT_US |
| 58467001 | SNOMEDCT_US |
| DAA13NKG2Q | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Papaverine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4002 | INJECTION, SOLUTION | 30 mg | INTRAVENOUS | unapproved drug other | 16 sections |
| Papaverine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-121 | INJECTION | 30 mg | INTRAVENOUS | unapproved drug other | 16 sections |
| PAPAVERINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54288-142 | INJECTION, SOLUTION | 30 mg | PARENTERAL | unapproved drug other | 16 sections |
| Papaverine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72516-024 | INJECTION, SOLUTION | 30 mg | INTRAVENOUS | unapproved drug other | 16 sections |